Role of CD20 expression and other pre-treatment risk factors in the development of infusion-related reactions in patients with CLL treated with obinutuzumab

被引：21
|
作者：
Freeman, C. L. [1 ]
Dixon, M. [2 ]
Houghton, R. [3 ]
Kreuzer, K-A [4 ,5 ]
Fingerle-Rowson, G. [6 ]
Herling, M. [4 ,5 ]
Humphrey, K. [7 ]
Boettcher, S. [8 ]
de Costa, C. S. [9 ]
Iglesias, V. [9 ]
Stilgenbauer, S. [10 ]
Gribben, J. [1 ]
Hallek, M. [4 ,5 ,11 ,12 ]
Goede, V. [4 ,5 ,11 ,12 ]
机构：
[1] Queen Mary Univ London, John Vane Canc Ctr, Barts Canc Inst, Dept Haematooncol, Charterhouse Sq, London, England
[2] Roche Prod Ltd, Dept Biostat, Welwyn Garden City, Herts, England
[3] Roche Prod Ltd, Dept Stat Programming & Anal, Welwyn Garden City, Herts, England
[4] German CLL Study Grp, Ctr Integrated Oncol Cologne, Bonn, Germany
[5] Univ Hosp Cologne, Dept Internal Med, Cologne, Germany
[6] F Hoffmann Roche Ltd, Pharma Dev Oncol, Basel, Switzerland
[7] Roche Prod Ltd, Pharma Dev Clin Sci, Welwyn Garden City, Herts, England
[8] Univ Hosp Schleswig Holstein, Campus Kiel, Kiel, Germany
[9] Roche Innovat Ctr Basel, PS, Roche Pharmaceut Res & Early Dev pRED, Basel, Switzerland
[10] Univ Ulm, Dept Internal Med 3, Ulm, Germany
[11] Ctr Integrated Oncol Koln, Dept Internal Med 1, Bonn, Germany
[12] Univ Cologne, Cluster Excellence Cellular Stress Responses Agin, Cologne, Germany
来源：
LEUKEMIA | 2016年 / 30卷 / 08期
关键词：
CHRONIC LYMPHOCYTIC-LEUKEMIA; IN-VITRO; RITUXIMAB; ANTIBODY; GA101;
D O I：
10.1038/leu.2016.41
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：1763 / 1766
页数：5
相关论文
共 13 条
  • [1] Role of CD20 expression and other pre-treatment risk factors in the development of infusion-related reactions in patients with CLL treated with obinutuzumab
    C L Freeman
    M Dixon
    R Houghton
    K-A Kreuzer
    G Fingerle-Rowson
    M Herling
    K Humphrey
    S Böttcher
    C S de Costa
    V Iglesias
    S Stilgenbauer
    J Gribben
    M Hallek
    V Goede
    Leukemia, 2016, 30 : 1763 - 1766
  • [2] Cytokine release in patients with CLL treated with obinutuzumab and possible relationship with infusion-related reactions
    Freeman, Ciara L.
    Morschhauser, Franck
    Sehn, Laurie
    Dixon, Mark
    Houghton, Richard
    Lamy, Thierry
    Fingerle-Rowson, Guenter
    Wassner-Fritsch, Elisabeth
    Gribben, John G.
    Hallek, Michael
    Salles, Gilles
    Cartron, Guillaume
    BLOOD, 2015, 126 (24) : 2646 - 2649
  • [3] Pre-treatment with Idelalisib markedly reduces Rituximab infusion-related reactions and infusion interruptions in patients with CLL
    Hallek, M.
    Hillmen, P.
    Furman, R. R.
    Coutre, S. E.
    Sharman, J. P.
    Pagel, J. M.
    Barrientos, J. C.
    Zelenetz, A. D.
    Kipps, T. J.
    Flinn, I. W.
    Ghia, P.
    Eradat, H.
    Erwin, T.
    Lamanna, N.
    Coiffier, B.
    Pettitt, A. R.
    O'Brien, S. M.
    Cheson, B. D.
    Ruppert, S.
    Kroenig, H.
    Schuster, A.
    ONCOLOGY RESEARCH AND TREATMENT, 2014, 37 : 52 - 53
  • [4] PRE-TREATMENT WITH IDELALISIB MARKEDLY REDUCES RITUXIMAB INFUSION-RELATED REACTIONS AND INFUSION INTERRUPTIONS IN PATIENTS WITH CLL
    Hillmen, P.
    Furman, R. R.
    Coutre, S. E.
    Sharman, J. P.
    Pagel, J. M.
    Barrientos, J. C.
    Zelenetz, A. D.
    Kipps, T. J.
    Flinn, I.
    Ghia, P.
    Eradat, H. A.
    Lamanna, N.
    Coiffier, B.
    Pettitt, A.
    Ye, W.
    Jahn, T. M.
    Dubowy, R.
    O'Brien, S. M.
    Hallek, M. J.
    Cheson, B. D.
    HAEMATOLOGICA, 2014, 99 : 55 - 55
  • [5] Bone marrow involvement is a risk factor for infusion-related reactions in patients with follicular lymphoma treated by obinutuzumab
    Yosuke Masamoto
    Kazuki Taoka
    Hiroaki Maki
    Mineo Kurokawa
    Annals of Hematology, 2022, 101 : 2795 - 2797
  • [6] Bone marrow involvement is a risk factor for infusion-related reactions in patients with follicular lymphoma treated by obinutuzumab
    Masamoto, Yosuke
    Taoka, Kazuki
    Maki, Hiroaki
    Kurokawa, Mineo
    ANNALS OF HEMATOLOGY, 2022, 101 (12) : 2795 - 2797
  • [7] Risk Factors Associated with the Development of Infusion-Related Reactions in Patients with Chronic Lymphocytic Leukaemia Treated with Anti-CD20 Monoclonal Antibodies: Analysis of the CLL11 Study Dataset
    Freeman, Ciara Louise
    Dixon, Mark
    Houghton, Richard
    Humphrey, Kathryn
    Fingerle-Rowson, Gunter
    Kreuzer, Karl-Anton
    Engelke, Anja
    Hallek, Michael
    Goede, Valentin
    BLOOD, 2014, 124 (21)
  • [8] Pretreatment with ibrutinib reduces cytokine secretion and limits the risk of obinutuzumab-induced infusion-related reactions in patients with CLL: analysis from the iLLUMINATE study
    Richard Greil
    Alessandra Tedeschi
    Carol Moreno
    Bertrand Anz
    Loree Larratt
    Martin Simkovic
    Devinder Gill
    John G. Gribben
    Ian W. Flinn
    Zhengyuan Wang
    Leo W. K. Cheung
    Aaron N. Nguyen
    Cathy Zhou
    Lori Styles
    Fatih Demirkan
    Annals of Hematology, 2021, 100 : 1733 - 1742
  • [9] Pretreatment with ibrutinib reduces cytokine secretion and limits the risk of obinutuzumab-induced infusion-related reactions in patients with CLL: analysis from the iLLUMINATE study
    Greil, Richard
    Tedeschi, Alessandra
    Moreno, Carol
    Anz, Bertrand
    Larratt, Loree
    Simkovic, Martin
    Gill, Devinder
    Gribben, John G.
    Flinn, Ian W.
    Wang, Zhengyuan
    Cheung, Leo W. K.
    Nguyen, Aaron N.
    Zhou, Cathy
    Styles, Lori
    Demirkan, Fatih
    ANNALS OF HEMATOLOGY, 2021, 100 (07) : 1733 - 1742
  • [10] Infusion-related reactions to infliximab (remicade®) in patients with rheumatoid arthritis:: Relationship to dose, anti-histamine pre-treatment and infusion number
    Wasserman, MJ
    Weber, DA
    Guthrie, JA
    Mitroi, E
    Bykerk, V
    Lee, P
    Keystone, EC
    JOURNAL OF RHEUMATOLOGY, 2003, 30 (08) : 1888 - 1888
12